Hypoxia and TLR9 activation drive CXCL4 production in systemic sclerosis plasmacytoid dendritic cells via mtROS and HIF-2α. (24th September 2021)
- Record Type:
- Journal Article
- Title:
- Hypoxia and TLR9 activation drive CXCL4 production in systemic sclerosis plasmacytoid dendritic cells via mtROS and HIF-2α. (24th September 2021)
- Main Title:
- Hypoxia and TLR9 activation drive CXCL4 production in systemic sclerosis plasmacytoid dendritic cells via mtROS and HIF-2α
- Authors:
- Ottria, Andrea
Zimmermann, Maili
Paardekooper, Laurent M
Carvalheiro, Tiago
Vazirpanah, Nadia
Silva-Cardoso, Sandra
Affandi, Alsya J
Chouri, Eleni
v.d Kroef, Maarten
Tieland, Ralph G
Bekker, Cornelis P J
Wichers, Catharina G K
Rossato, Marzia
Mocholi-Gimeno, Enric
Tekstra, Janneke
Ton, Evelien
van Laar, Jaap M
Cossu, Marta
Beretta, Lorenzo
Garcia Perez, Samuel
Pandit, Aridaman
Bonte-Mineur, Femke
Reedquist, Kris A
van den Bogaart, Geert
Radstake, Timothy R D J
Marut, Wioleta - Abstract:
- Abstract: Objective: SSc is a complex disease characterized by vascular abnormalities and inflammation culminating in hypoxia and excessive fibrosis. Previously, we identified chemokine (C-X-C motif) ligand 4 (CXCL4) as a novel predictive biomarker in SSc. Although CXCL4 is well-studied, the mechanisms driving its production are unclear. The aim of this study was to elucidate the mechanisms leading to CXCL4 production. Methods: Plasmacytoid dendritic cells (pDCs) from 97 healthy controls and 70 SSc patients were cultured in the presence of hypoxia or atmospheric oxygen level and/or stimulated with several toll-like receptor (TLR) agonists. Further, pro-inflammatory cytokine production, CXCL4, hypoxia-inducible factor (HIF) -1α and HIF-2α gene and protein expression were assessed using ELISA, Luminex, qPCR, FACS and western blot assays. Results: CXCL4 release was potentiated only when pDCs were simultaneously exposed to hypoxia and TLR9 agonist ( P < 0.0001). Here, we demonstrated that CXCL4 production is dependent on the overproduction of mitochondrial reactive oxygen species (mtROS) ( P = 0.0079) leading to stabilization of HIF-2α ( P = 0.029). In addition, we show that hypoxia is fundamental for CXCL4 production by umbilical cord CD34 derived pDCs. Conclusion: TLR-mediated activation of immune cells in the presence of hypoxia underpins the pathogenic production of CXCL4 in SSc. Blocking either mtROS or HIF-2α pathways may therapeutically attenuate the contributionAbstract: Objective: SSc is a complex disease characterized by vascular abnormalities and inflammation culminating in hypoxia and excessive fibrosis. Previously, we identified chemokine (C-X-C motif) ligand 4 (CXCL4) as a novel predictive biomarker in SSc. Although CXCL4 is well-studied, the mechanisms driving its production are unclear. The aim of this study was to elucidate the mechanisms leading to CXCL4 production. Methods: Plasmacytoid dendritic cells (pDCs) from 97 healthy controls and 70 SSc patients were cultured in the presence of hypoxia or atmospheric oxygen level and/or stimulated with several toll-like receptor (TLR) agonists. Further, pro-inflammatory cytokine production, CXCL4, hypoxia-inducible factor (HIF) -1α and HIF-2α gene and protein expression were assessed using ELISA, Luminex, qPCR, FACS and western blot assays. Results: CXCL4 release was potentiated only when pDCs were simultaneously exposed to hypoxia and TLR9 agonist ( P < 0.0001). Here, we demonstrated that CXCL4 production is dependent on the overproduction of mitochondrial reactive oxygen species (mtROS) ( P = 0.0079) leading to stabilization of HIF-2α ( P = 0.029). In addition, we show that hypoxia is fundamental for CXCL4 production by umbilical cord CD34 derived pDCs. Conclusion: TLR-mediated activation of immune cells in the presence of hypoxia underpins the pathogenic production of CXCL4 in SSc. Blocking either mtROS or HIF-2α pathways may therapeutically attenuate the contribution of CXCL4 to SSc and other inflammatory diseases driven by CXCL4. … (more)
- Is Part Of:
- Rheumatology. Volume 61:Number 6(2022)
- Journal:
- Rheumatology
- Issue:
- Volume 61:Number 6(2022)
- Issue Display:
- Volume 61, Issue 6 (2022)
- Year:
- 2022
- Volume:
- 61
- Issue:
- 6
- Issue Sort Value:
- 2022-0061-0006-0000
- Page Start:
- 2682
- Page End:
- 2693
- Publication Date:
- 2021-09-24
- Subjects:
- CXCL4 -- plasmacytoid dendritic cells -- hypoxia -- TLRs -- mtROS -- HIF-2α -- systemic sclerosis
Rheumatism -- Periodicals
Rheumatology -- Periodicals
616.723005 - Journal URLs:
- http://rheumatology.oupjournals.org ↗
http://rheumatology.oxfordjournals.org ↗
http://ukcatalogue.oup.com/ ↗
http://firstsearch.oclc.org ↗ - DOI:
- 10.1093/rheumatology/keab532 ↗
- Languages:
- English
- ISSNs:
- 1462-0324
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7960.731900
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21768.xml